Recently published in Brain, Gonzalez-Ortiz et al. report the design and development of a novel blood-based biomarker specific to brain-derived tau. In this blog post, we dive into the advantages of their novel immunoassay over those that are commercially available, as well as its future implications for Alzheimer’s disease diagnosis.
Triple-negative breast cancer is particularly aggressive, challenging to treat, and accounts for 15-20% of all breast cancers. In this blog, we review a study published in Nature Communications that examines the transforming growth factor-β targetable signaling pathway, its role in malignant cancer progression and immune suppression, and tumor-derived extracellular vesicles as diagnostic and prognostic biomarkers.
Dr. Bonnie Lun from Fortis Life Sciences discusses applications and advantages of using nanobodies for diagnostic and therapeutic research, and highlights Fortis/Abcore's single-domain antibody discovery services.